Anaptysbio (ANAB) Cash from Financing Activities (2016 - 2026)

Anaptysbio (ANAB) has 11 years of Cash from Financing Activities data on file, last reported at $1.2 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 104.23% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$102.8 million (down 191.72% YoY) and the FY2025 annual result came in at -$132.6 million, down 204.38% from the prior year.
• Cash from Financing Activities advanced to $1.2 million in Q1 2026, from -$43.1 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $71.2 million in Q3 2024 to a low of -$50.5 million in Q2 2025.
• A 5-year average of -$1.2 million and a median of -$3.1 million in 2023 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities surged 15263.9% — and 2023, when it sank 3223.15%.
• Tracing ANAB's Cash from Financing Activities over 5 years: stood at $1.9 million in 2022, then sank by 364.7% to -$5.2 million in 2023, then surged by 634.35% to $27.6 million in 2024, then sank by 256.47% to -$43.1 million in 2025, then surged by 102.8% to $1.2 million in 2026.
• The last three Cash from Financing Activities figures came in at $1.2 million (Q1 2026), -$43.1 million (Q4 2025), and -$10.4 million (Q3 2025), per Business Quant data.